



Using a clinicopathologic and gene expression model to predict sentinel lymph node metastasis in primary cutaneous melanoma could reduce the rate of sentinel lymph node biopsies with >70%: a multicentre Danish cohort study

Dr Marie Weitemeyer¹, Dr Neel Maria Helvind¹, Dr Annette Hougaard Chakera¹, Dr Siri Klausen², Dr Erik Clasen-Linde², MD Grethe Schmidt³, Professor Lisbet Rosenkrantz Hoelmich¹

1 Department of Plastic Surgery, Copenhagen University Hospital – Herlev and Gentofte, Herlev, Denmark /

2 Department of Pathology, Copenhagen University Hospital – Herlev and Gentofte, Herlev, Denmark /

3 Department of Plastic Surgery and Burns Treatment, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark

Abstract at EADO 2023



Background: Sentinel lymph node biopsy (SLNB) is the standard procedure for staging in primary cutaneous melanoma and is used to guide subsequent management. It is, however, an invasive procedure with associated risks and proper patient selection for SLNB remains a challenge; approx. 80% of all SLNB are negative, with even higher negative rates when looking only at thin melanoma (T1) which account for the vast majority of cases. The clinicopathological and gene expression profile (CP-GEP) model was developed to identify low risk melanoma patients who may safely forgo SLNB. The CP-GEP model combines Breslow thickness and patient age with the expression of eight genes to classify patients as high or low-risk for nodal metastasis.

This study presents data from an independent validation of the CP-GEP model in a multicenter Danish cohort.

Materials and Methods: Archived formalin-fixed paraffin-embedded primary melanoma tissue from 537 T1-T3 cutaneous melanoma patients was collected and analysed with CP-GEP in a prospectively designed study. The patients had undergone SLNB between 2010 and 2015 at either of two university clinics in Denmark. The CP-GEP result was compared with the SLNB result, calculating the diagnostic value of CP-GEP for SLNB metastasis.

Results: Median age at diagnosis was 58 years (interquartile range [IQR] 44-70) and median Breslow thickness was 1.3mm (IQR 0.95-1.82). The distribution of T1, T2 and T3 melanoma was 32.8%, 46.9% and 20.3%, respectively. The SLNB positivity rate was 18.1%. The CP-GEP model identified 219 (40.8%) patients as having a low risk for nodal metastasis with a NPV of 91.3%. When analysing the T1 subgroup (n=176) the CP-GEP low risk rate was 72.7% with an NPV of 94.5%.

Conclusion: The CP-GEP model accurately identifies patients at low risk for SN metastasis, and especially in patients with T1 melanoma. Results are in line with previous retrospective validation studies on European and US cohorts, however, this study contain the largest T1 subgroup validation with a potential very high SLNB reduction rate found for this subgroup. The CP-GEP is a promising risk stratification tool for melanoma patients, potentially preventing unnecessary surgery in a large group of patients.
